Ghostwriting at Elite Academic Medical Centers in the United States

Overview

Journal PLoS Med

Specialty General Medicine

Date 2010 Feb 4

PMID 20126384

Citations 15

Authors

Jeffrey R Lacasse

Jonathan Leo

Affiliations

Soon will be listed here.

Citing Articles

Publication of observational studies making claims of causation over time.

Haslam A, Prasad V Contemp Clin Trials Commun. 2024; 40:101327.

PMID: 39036556 PMC: 11259777. DOI: 10.1016/j.conctc.2024.101327.

Describing the Attributional Nature of Academic Dishonesty.

Henning M, Chen Y, Ram S, Malpas P Med Sci Educ. 2021; 29(2):577-581.

PMID: 34457515 PMC: 8368338. DOI: 10.1007/s40670-019-00710-8.

Authorship Policies at U.S. Doctoral Universities: A Review and Recommendations for Future Policies.

Rasmussen L, Williams C, Hausfeld M, Banks G, Davis B Sci Eng Ethics. 2020; 26(6):3393-3413.

PMID: 33210194 PMC: 7755643. DOI: 10.1007/s11948-020-00273-7.

Perish or Publish Dilemma: Challenges to Responsible Authorship.

Aliukonis V, Poskute M, Gefenas E Medicina (Kaunas). 2020; 56(3).

PMID: 32178434 PMC: 7142498. DOI: 10.3390/medicina56030123.

Authors' awareness of concepts in the authorship of scientific publications: Viewpoints of the dental faculty in India.

Punyani S, Deshpande A J Oral Biol Craniofac Res. 2018; 8(3):151-153.

PMID: 30191098 PMC: 6108114. DOI: 10.1016/j.jobcr.2016.05.001.

References

Berenson A . Evidence in Vioxx suits shows intervention by Merck officials. N Y Times Web. 2005; :A1, A32. View

Ross J, Hill K, Egilman D, Krumholz H . Guest authorship and ghostwriting in publications related to rofecoxib: a case study of industry documents from rofecoxib litigation. JAMA. 2008; 299(15):1800-12. DOI: 10.1001/jama.299.15.1800. View

McHenry L, Jureidini J . Industry-sponsored ghostwriting in clinical trial reporting: a case study. Account Res. 2008; 15(3):152-67. DOI: 10.1080/08989620802194384. View

Elliott C . Pharma goes to the laundry: Public relations and the business of medical education. Hastings Cent Rep. 2004; 34(5):18-23. View

Healy D, Cattell D . Interface between authorship, industry and science in the domain of therapeutics. Br J Psychiatry. 2003; 183:22-7. View

Sismondo S . Ghosts in the machine: publication planning in the medical sciences. Soc Stud Sci. 2009; 39(2):171-98. DOI: 10.1177/0306312708101047. View

Keller M, Ryan N, Strober M, Klein R, Kutcher S, Birmaher B . Efficacy of paroxetine in the treatment of adolescent major depression: a randomized, controlled trial. J Am Acad Child Adolesc Psychiatry. 2001; 40(7):762-72. DOI: 10.1097/00004583-200107000-00010. View

Sismondo S, Doucet M . Publication ethics and the ghost management of medical publication. Bioethics. 2009; 24(6):273-83. DOI: 10.1111/j.1467-8519.2008.01702.x. View

. Ghostwriting: the dirty little secret of medical publishing that just got bigger. PLoS Med. 2009; 6(9):e1000156. PMC: 2734179. DOI: 10.1371/journal.pmed.1000156. View

10.

Steinman M, Bero L, Chren M, Landefeld C . Narrative review: the promotion of gabapentin: an analysis of internal industry documents. Ann Intern Med. 2006; 145(4):284-93. DOI: 10.7326/0003-4819-145-4-200608150-00008. View

11.

Fugh-Berman A, Dodgson S . Ethical considerations of publication planning in the pharmaceutical industry. Open Med. 2011; 2(4):e121-4. PMC: 3091612. View

12.

McHenry L . On the origin of great ideas: science in the age of big pharma. Hastings Cent Rep. 2006; 35(6):17-9. View

13.

Moffatt B, Elliott C . Ghost marketing: pharmaceutical companies and ghostwritten journal articles. Perspect Biol Med. 2007; 50(1):18-31. DOI: 10.1353/pbm.2007.0009. View

14.

Gotzsche P, Kassirer J, Woolley K, Wager E, Jacobs A, Gertel A . What should be done to tackle ghostwriting in the medical literature?. PLoS Med. 2009; 6(2):e23. PMC: 2634793. DOI: 10.1371/journal.pmed.1000023. View